Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (February 2026)
19 slides from Rhythm Biosciences's investor presentation, Feb 16, 2026
Slide 1: Business Update February 2026
For personal use only Business Update FEBRUARY 2026
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, rep
Slide 3: Detecting Cancer Earlier. Saving Lives.
Detecting Cancer Earlier. Saving Lives. Our purpose is clear: through innovative diagnostics, we are enabling the earliest possible detection of cancer. For personal use only Product Strategy Growth Opportunity and Drivers EARLIEST STAGE SIGNIFICANT MULTI-$BN GLOBAL MARKET geneTypeTM Targeting the r
Slide 4: Cancer is an increasing burden on global healthcare systems
Cancer is an increasing burden on global healthcare systems The role of cancer diagnostics remains critical to public health Estimated % rise in all cancers Estimated number of worldwide 2022 to 2050 prevalent cases in 5 years from 2022 For personal use only Males and Females, Age 0-85+ Incidence: 8
Slide 5: When diagnosed early, cancer can be successfully treated
When diagnosed early, cancer can be successfully treated Disease stage for colorectal cancer diagnosis is the key predictor of survival Diagnoses at Stage I or II only represent less than half of all CRCs diagnosed: For personal use only Missed detection of early-stage CRC results in poor survival r
Slide 6: Detecting Cancer Earlier and Maintaining Health and Wellness
Detecting Cancer Earlier and Maintaining Health and Wellness The power of the combination of the Rhythm capabilities and portfolio For personal use only Y N E U R Risk Assessment Disease Screening O J MONITORING AND Determination Minimally-invasive detection MINIMAL RESIDUAL T RISK ASSESSMENT DISEAS
Slide 7: ColoSTAT: A new to the market clinical test for bowel cancer
ColoSTAT®: A new to the market clinical test for bowel cancer For personal use only ColoSTAT® has been developed as an alternative, blood-based solution for use in the detection of colorectal cancer A high quality, Initial intended use is for higher risk, symptomatic individuals who are seeking an a
Slide 8: ColoSTAT: Addressing Multiple Clinical Use Cases
ColoSTAT®: Addressing Multiple Clinical Use Cases Clinical use will commence with triage and build to screening Triage Market Size: 22M Tests1 For personal use only Unwilling to perform stool test (annual tests) +ROW: 1.6m >55% of free public tests are declined +ASPAC: 2.7m +EU/UK: 4m Too fragile or
Slide 9: ColoSTAT FY26 Regulatory Strategy
ColoSTAT® FY26 Regulatory Strategy Two major sequential strategies available for novel diagnostic products In House In Vitro Diagnostic Service Diagnostic Product For personal use only 1. Validation of clinical laboratory capability Provides approval to provide a clinical service 1. Submission of do
Slide 10: ColoSTAT FY26 Commercial Strategy
ColoSTAT® FY26 Commercial Strategy Launch with a focus on patient safety and clinical efficacy ColoSTAT® Access Program NHS Bowel Cancer Screening Program For personal use only Patient symptomatic Blood sample collected Program Background: for bowel cancer consults GP at phlebotomy service • Stool-b
Slide 11: Genetype: A novel cancer risk assessment clinical testing portfolio
Genetype: A novel cancer risk assessment clinical testing portfolio For personal use only A cancer risk assessment platform designed for sporadic cancer risk A unique, integrated, Scope includes 6 cancers with validation data on 100,000s of individuals personalized cancer risk assessment platform le
Slide 12: A novel, personalised clinical risk assessment
A novel, personalised clinical risk assessment A unique clinically validated method to allow individuals to understand and manage their cancer risk For personal use only RISK RISK TAILORED Genetype Clinical Applications ASSESSMENT STRATIFICATION SCREENING • Individualized patient care • Institutiona
Slide 13: Genetype FY26 Commercial Strategy
Genetype FY26 Commercial Strategy Genetype Target Segments Oncology Channel Portfolio Strategy For personal use only Focus • Health Care Professionals – B2B • Breast* Volume from enterprise accounts & • Strategic partners/ • Prostate Enterprise accounts - strategic partners B2B2B • Colorectal* • Ova
Slide 14: 3-Year Business Growth Plan
3-Year Business Growth Plan Leveraging our core business enablers to build a resilient high growth enterprise For personal use only Product Development Optimise delivery of current portfolio Portfolio Expansion Commercial Depth Market Expansion Pilot Markets and GTM optimisation Global Expansion Glo
Slide 15: Investment Highlights
Investment Highlights CORPORATE SNAPSHOT 13th February 2025 Solving a significant and worsening global ASX Code RHY problem costing healthcare systems $billions For personal use only Share Price $0.21 Shares on Issue 329.5M Unlisted & Listed Options 52.5M Market Capitalisation $78.5M Portfolio of va
Slide 16: Upcoming value inflection points
Upcoming value inflection points For personal use only PRODUCT ITEM DESCRIPTION COMPLETION DATE Completion of NATA audit and accreditation of ColoSTAT® Assay Accreditation Q3 FY2026 ColoSTAT® geneType strategic Establishment of key international and domestic geneType Q3 FY2026 partnerships commercia
Slide 17: Board and Management Team
Board and Management Team Highly experienced team focussed on execution For personal use only Jackson Jones Nir Dvorski Chief Commercial Officer Chief Operations Officer David Atkins, PhD Sue MacLeman Gavin Fox-Smith CEO & MD Non-Executive Director Non-Executive Chairman Former CEO of Congenica (UK)
Slide 18: Selected Recent Market Updates
Selected Recent Market Updates Placing selected news from the last 2 months in context Business Segment Market Update Topic Significance to the Business Impact Date For personal use only ColoSTAT® Access Independent professional validation Clinical adoption Program, 1st Physician of ColoSTAT® as a v
Slide 19: Thank you!
For personal use only Thank you! david.atkins@rhythmbio.com www.rhythmbio.com
Rhythm Biosciences — Investor Presentation (February 2026) on 6ix